M
MANGOCEUTICALS, INC.
MGRXCIK 0001938046NasdaqEmerging GrowthServices-Misc Health & Allied Services, NecTexasFY ends Dec 31
Period
FY 2025
Revenue
$456.0K
Net Income
$-20.64M
Total Assets
$16.09M
Equity
$15.20M
Shares Out
17.17M
Op. Cash Flow
$-5.85M
Business
Mangoceuticals, Inc. operates a telemedicine platform connecting consumers to licensed healthcare professionals for men's wellness treatments via telehealth. The company develops and markets compounded pharmaceutical products under brand names Mango (erectile dysfunction), Grow (hair loss), Mojo (hormone balance), and Slim (weight management), along with Prime, an FDA-approved oral testosterone replacement therapy. Products are fulfilled by related-party pharmacy Epiq Scripts and distributed through the MangoRx portal, with expansion into international markets and new therapeutic areas including respiratory illness prevention and dermatology treatments.
Summary from 10-K filed 2026-04-01
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Revenues | 456,021 | 615,873 | 731,493 | 8,939 | |
| Cost of revenues | 54,422 | 93,296 | 154,900 | 4,089 | |
| Cost of revenues - related party | 151,213 | 142,613 | 145,092 | — | |
| Gross profit | 250,386 | 379,964 | 431,501 | 4,850 | |
| General and administrative expenses | 4 | 3 | 3 | 2 | |
| Salary and benefits | 1 | 1 | 977,890 | — | |
| Advertising and marketing | 822,860 | 1 | 2 | 352,860 | |
| Investor relations | 2 | 453,749 | 1 | — | |
| Stock based compensation | 11 | 2 | 2 | — | |
| Total operating expenses | 18 | 8 | 10 | 2 | |
| Loss from operations | −18 | −8 | −9 | −2 | |
| Interest expense | 103,513 | 13,700 | — | — | |
| Amortization of intangible assets | 1 | 721,533 | — | — | |
| Impairment of license agreement | 1 | — | — | — | |
| Loss from settlement | 125,624 | — | — | — | |
| Loss from debt extinguishment - related parties | 19,388 | — | — | — | |
| Total other (income) expense | 3 | 735,233 | −6,473 | 6,473 | |
| Loss before income taxes | −21 | −9 | −9 | −2 | |
| Income taxes | — | — | — | — | |
| Net loss | −21 | −9 | −9 | — | |
| Net loss attributed to non-controlling interest | −461 | −1,081 | — | — | |
| Net loss attributed to Mangoceuticals, Inc. | −21 | −9 | −9 | −2 | |
| Basic loss per share | −2.17 | −4.8 | −8.58 | −0.19 | |
| Diluted loss per share | −2.17 | −4.8 | −8.58 | −0.19 | |
| Basic | 10 | 2 | 1 | 11 | |
| Diluted | 10 | 2 | 1 | 11 | |
| Preferred stock dividend requirements | 1 | 802,109 | — | — | |
| Net loss attributed to Mangoceuticals, Inc. common stockholders | −22 | −10 | — | — |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 1 | 58,653 | 739,006 | 682,860 | — | |
| Deposits | 33,899 | 16,942 | 16,942 | — | — | |
| Due from related party | 20,056 | — | — | — | — | |
| TOTAL CURRENT ASSETS | 2 | 75,595 | 835,402 | 694,605 | — | |
| Property and equipment, net of accumulated depreciation of $1,012 and $2,256 | 1,794 | 2,806 | 96,129 | 117,499 | — | |
| Right of use - asset | 307,861 | 59,493 | 119,262 | 174,241 | — | |
| Intangible assets - acquired patents and license, net of amortization and impairment | 14 | 15 | — | — | — | |
| TOTAL NON-CURRENT ASSETS | 15 | 15 | 215,391 | — | — | |
| TOTAL ASSETS | 16 | 15 | 1 | 1 | — | |
| Accounts payable and accrued liabilities | 416,682 | 837,501 | 140,765 | 33,675 | — | |
| Payroll tax liabilities | 9,421 | — | 6,595 | 2,717 | — | |
| Notes payable | — | 150,000 | — | — | — | |
| Right-of-use liability - operating lease | 307,823 | 64,962 | 63,718 | 56,725 | — | |
| TOTAL CURRENT LIABILITIES | 890,568 | 1 | 211,078 | 260,577 | — | |
| TOTAL LIABILITIES | 890,568 | 1 | 276,039 | 389,257 | — | |
| Common stock (par value $0.0001), 200,000,000 shares authorized, of which 15,888,795 and 3,245,641 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 1,589 | 325 | 148 | 1,337 | — | |
| Stock warrants | 324,288 | 324,288 | — | — | — | |
| Subscription receivable | — | −1 | — | — | — | |
| Additional paid in capital | 56 | 35 | 12 | 3 | — | |
| Accumulated deficit | −41 | −20 | −11 | −2 | — | |
| Accumulated other comprehensive loss | −2,760 | −9,845 | — | — | — | |
| TOTAL STOCKHOLDERS EQUITY | 15 | 14 | 774,754 | 614,030 | −16,720 | |
| Non-controlling interest | −1,542 | −1,081 | — | — | — | |
| TOTAL STOCKHOLDERS EQUITY | 15 | 14 | 774,754 | 614,029 | — | |
| TOTAL LIABILITIES AND STOCKHOLDERS EQUITY | 16 | 15 | 1 | 1 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Depreciation | 1,012 | 9,936 | 24,889 | 3,863 | |
| Issuance of common stock for services | 11 | 2 | 2 | — | |
| Options vested for stock-based compensation | 1 | 248,682 | 624,463 | 234,088 | |
| Loss on sale of assets | — | 18,387 | — | — | |
| Amortization of license agreement | 600,552 | — | — | — | |
| Operating lease right of use asset | 68,539 | 59,769 | 54,979 | −174,241 | |
| Inventory obsolescence | — | 18,501 | — | — | |
| Deposits | −16,957 | — | — | — | |
| Accounts payable and accrued liabilities | 55,669 | 696,736 | 107,090 | — | |
| Accrued liabilities - related parties | — | −63,717 | — | — | |
| Operating lease right-of-use liabilities | −74,046 | −6,595 | −56,726 | 185,405 | |
| Payroll tax liabilities | 9,421 | — | 3,878 | 2,717 | |
| Other liabilities | −216,358 | −27,000 | — | — | |
| NET CASH USED IN OPERATING ACTIVITIES | −6 | −5 | −7 | −1 | |
| Sale of assets | — | 65,000 | — | — | |
| NET CASH PROVIDED BY(USED IN) INVESTING ACTIVITIES | — | 65,000 | −3,519 | −43,102 | |
| Proceeds from borrowings on notes payable | 500,000 | 150,000 | −78,260 | — | |
| Proceeds from borrowings on notes payable - related parties | 175,000 | — | — | — | |
| Proceeds from sales of common stock | 5 | 1 | 6 | 2 | |
| Proceeds from sales of series B convertible preferred stock | 100,000 | 3 | — | — | |
| Proceeds from exercise of warrants | 927,000 | — | 1 | — | |
| Collection of subscriptions receivable | 1 | — | — | — | |
| Repayment of borrowings on notes payable - related parties | −206,500 | — | −89,200 | −25,070 | |
| NET CASH PROVIDED BY FINANCING ACTIVITIES | 7 | 4 | 7 | 2 | |
| End of period | 1 | −670,508 | 56,146 | — | |
| Effects of currency translation on cash and cash equivalents | 7,085 | −9,845 | — | — | |
| Cash paid for income taxes | — | — | — | — | |
| Cash paid for interest | — | — | — | — | |
| Right of use assets acquired under new operating leases | 316,907 | — | — | — | |
| Issuance of common stock for license agreement | 2 | — | — | — | |
| Issuance of common stock for patent acquisition | — | 1 | — | — | |
| Issuance of Series C Convertible Preferred for patent acquisition | — | 14 | — | — | |
| Issuance of common stock for payment of Preferred B dividend | — | 70,168 | — | — | |
| Issuance of common stock for settlement of debt settlement | 590,000 | — | — | — | |
| Issuance of common stock for settlement of note payable | 500,000 | — | — | — | |
| Issuance of common stock for settlement of note payable - related parties | 150,000 | — | — | — | |
| Issuance of common stock for conversion of Series B Convertible Preferred | 201 | 1 | — | — | |
| Issuance of common stock for cashless warrant exercise | 23 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is MANGOCEUTICALS, INC.'s CIK number?
MANGOCEUTICALS, INC.'s SEC CIK number is 0001938046 (1938046). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find MANGOCEUTICALS, INC.'s SEC filings?
All of MANGOCEUTICALS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.